Plant Name: Rhodomyrtus tomentosa
Taxonomic Information:
Plant ID: NPO13106
Plant Latin Name: Rhodomyrtus tomentosa
Taxonomy Genus: Rhodomyrtus
Taxonomy Family: Myrtaceae
Plant External Links:
NCBI TaxonomyDB:
98583
Plant-of-the-World-Online:
n.a.
Used in Medicines:
Country/Region:
Malaysia; Indonesia; China; IndiaTraditional Medicine System:
Indian Folk; TCM; SiddhaGeographical Distribution:
India; Indonesia; China; Malaysia
Geographical Distribution
See the Plant Occurrence Worldwide with Latitude and Longitude Available
Collective Molecular Activities of the Plant
List of Human Proteins Collectively Targeted by the Plant
Click Gene ID to Access Activity Profile of Individual Target
| GPBAR1; | |
| TSHR; | |
| CDA; TK1; PKM; AKR1B1; ALOX15; AKR1B10; | |
| TRPA1; | |
| CA12; CA9; | |
| NR1H4; | |
| PTGS1; XDH; | |
| F10; | |
| CASP1; CASP7; | |
| HIF1A; | |
| SLC28A1; SLC28A3; | |
| HTT; LMNA; MAPT; THPO; |
List of Human Cytochrome P450 Enzymes Affected by the Plant
Click Gene ID to Access Activity Profile of Individual Enzyme
Detailed Information of Target Proteins
| Protein Class | Gene ID | Protein Name | Uniprot ID | Target ChEMBL ID |
|---|---|---|---|---|
| Cysteine protease | CASP1 | Caspase-1 | P29466 | CHEMBL4801 |
| Cysteine protease | CASP7 | Caspase-7 | P55210 | CHEMBL3468 |
| Cytochrome P450 family 1 | CYP1A2 | Cytochrome P450 1A2 | P05177 | CHEMBL3356 |
| Cytochrome P450 family 2 | CYP2C19 | Cytochrome P450 2C19 | P33261 | CHEMBL3622 |
| Cytochrome P450 family 2 | CYP2C9 | Cytochrome P450 2C9 | P11712 | CHEMBL3397 |
| Cytochrome P450 family 2 | CYP2D6 | Cytochrome P450 2D6 | P10635 | CHEMBL289 |
| Cytochrome P450 family 3 | CYP3A4 | Cytochrome P450 3A4 | P08684 | CHEMBL340 |
| Enzyme_unclassified | CDA | Cytidine deaminase | P32320 | CHEMBL4502 |
| Enzyme_unclassified | TK1 | Thymidine kinase, cytosolic | P04183 | CHEMBL2883 |
| Enzyme_unclassified | PKM | Pyruvate kinase isozymes M1/M2 | P14618 | CHEMBL1075189 |
| Enzyme_unclassified | AKR1B1 | Aldose reductase | P15121 | CHEMBL1900 |
| Enzyme_unclassified | ALOX15 | Arachidonate 15-lipoxygenase | P16050 | CHEMBL2903 |
| Enzyme_unclassified | AKR1B10 | Aldo-keto reductase family 1 member B10 | O60218 | CHEMBL5983 |
| Lyase | CA12 | Carbonic anhydrase XII | O43570 | CHEMBL3242 |
| Lyase | CA9 | Carbonic anhydrase IX | Q16790 | CHEMBL3594 |
| Nuclear hormone receptor subfamily 1 group H | NR1H4 | Bile acid receptor FXR | Q96RI1 | CHEMBL2047 |
| Oxidoreductase | PTGS1 | Cyclooxygenase-1 | P23219 | CHEMBL221 |
| Oxidoreductase | XDH | Xanthine dehydrogenase | P47989 | CHEMBL1929 |
| Peptide receptor (family A GPCR) | TSHR | Thyroid stimulating hormone receptor | P16473 | CHEMBL1963 |
| Serine protease | F10 | Coagulation factor X | P00742 | CHEMBL244 |
| SLC superfamily of solute carriers | SLC28A1 | Sodium/nucleoside cotransporter 1 | O00337 | CHEMBL5551 |
| SLC superfamily of solute carriers | SLC28A3 | Solute carrier family 28 member 3 | Q9HAS3 | CHEMBL5707 |
| Small molecule receptor (family A GPCR) | GPBAR1 | G-protein coupled bile acid receptor 1 | Q8TDU6 | CHEMBL5409 |
| Transcription Factor | HIF1A | Hypoxia-inducible factor 1 alpha | Q16665 | CHEMBL4261 |
| Transient receptor potential channel | TRPA1 | Transient receptor potential cation channel subfamily A member 1 | O75762 | CHEMBL6007 |
| Unclassified | HTT | Huntingtin | P42858 | CHEMBL5514 |
| Unclassified | LMNA | Prelamin-A/C | P02545 | CHEMBL1293235 |
| Unclassified | MAPT | Microtubule-associated protein tau | P10636 | CHEMBL1293224 |
| Unclassified | THPO | Thrombopoietin | P40225 | CHEMBL1293256 |
Enrichment of Gene Ontology of Target Proteins (Activity≤10μM)
Detailed Information of Enriched Gene Ontolgy
| GO Type | GO Category | Enriched GO Terms | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|
| BP | GO:0008152; metabolic process | GO:0016098; monoterpenoid metabolic process | 3.178E-14 | 6.920E-10 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0050896; response to stimulus | GO:0042738; exogenous drug catabolic process | 2.011E-09 | 6.759E-06 | CYP1A2, CYP2C19, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0070989; oxidative demethylation | 2.011E-09 | 6.759E-06 | CYP1A2, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0008202; steroid metabolic process | 2.173E-09 | 6.759E-06 | AKR1B1, AKR1B10, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, NR1H4 |
| MF | GO:0005488; binding | GO:0005506; iron ion binding | 3.141E-09 | 8.548E-06 | ALOX15, CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, XDH |
| MF | GO:0005488; binding | GO:0019825; oxygen binding | 6.215E-09 | 1.353E-05 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| MF | GO:0003824; catalytic activity | GO:0034875; caffeine oxidase activity | 1.216E-08 | 1.765E-05 | CYP1A2, CYP2C9, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0006805; xenobiotic metabolic process | 1.574E-08 | 2.142E-05 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1 |
| MF | GO:0005488; binding | GO:0020037; heme binding | 3.155E-08 | 3.425E-05 | CYP1A2, CYP2C19, CYP2C9, CYP2D6, CYP3A4, PTGS1 |
| MF | GO:0003824; catalytic activity | GO:0008395; steroid hydroxylase activity | 1.841E-07 | 1.485E-04 | CYP2C19, CYP2C9, CYP2D6, CYP3A4 |
| BP | GO:0008152; metabolic process | GO:0097267; omega-hydroxylase P450 pathway | 3.625E-07 | 2.722E-04 | CYP1A2, CYP2C19, CYP2C9 |
| MF | GO:0005215; transporter activity | GO:0015389; pyrimidine- and adenine-specific:sodium symporter activity | 2.176E-06 | 1.394E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0019373; epoxygenase P450 pathway | 3.974E-06 | 2.404E-03 | CYP1A2, CYP2C19, CYP2C9 |
| BP | GO:0009987; cellular process | GO:0051289; protein homotetramerization | 4.383E-06 | 2.512E-03 | CDA, PKM, TK1, TRPA1 |
| BP | GO:0051179; localization | GO:1904823; purine nucleobase transmembrane transport | 6.523E-06 | 2.924E-03 | SLC28A1, SLC28A3 |
| BP | GO:0008152; metabolic process | GO:0009822; alkaloid catabolic process | 6.523E-06 | 2.924E-03 | CYP2D6, CYP3A4 |
| BP | GO:0051179; localization | GO:0015855; pyrimidine nucleobase transport | 6.523E-06 | 2.924E-03 | SLC28A1, SLC28A3 |
| BP | GO:0009987; cellular process | GO:0038183; bile acid signaling pathway | 6.523E-06 | 2.924E-03 | GPBAR1, NR1H4 |
| BP | GO:0065007; biological regulation | GO:0006919; activation of cysteine-type endopeptidase activity involved in apoptotic process | 6.608E-06 | 2.924E-03 | CASP1, CASP7, MAPT, XDH |
| MF | GO:0003824; catalytic activity | GO:0070330; aromatase activity | 5.281E-06 | 2.924E-03 | CYP1A2, CYP2D6, CYP3A4 |
| MF | GO:0060089; molecular transducer activity | GO:0038181; bile acid receptor activity | 6.523E-06 | 2.924E-03 | GPBAR1, NR1H4 |
| CC | GO:0044464; cell part | GO:0032838; plasma membrane bounded cell projection cytoplasm | 1.366E-04 | 3.585E-02 | AKR1B1, HIF1A, MAPT |
Enriched KEGG Pathways of Target Proteins (Activity≤10μM)
Top 10 KEGG Pathways (ordered by adjusted p-value)
Detailed Information of Enriched KEGG Pathways
| Pathway Category Top Level | Pathway Category Second Level | Pathway ID | Pathway Name | p-Value | Adjusted p-Value | Enriched Genes |
|---|---|---|---|---|---|---|
| 09100 Metabolism | 09103 Lipid metabolism | hsa00591 | Linoleic acid metabolism | 5.166E-10 | 3.254E-08 | CYP2C9, CYP1A2, ALOX15, CYP3A4, CYP2C19 |
| Unclassified | Unclassified | hsa01100 | Metabolic pathways | 5.866E-08 | 1.232E-06 | CYP2C9, CDA, PKM, AKR1B10, CYP1A2, ALOX15, AKR1B1, TK1, CYP2C19, CYP3A4, XDH, PTGS1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00982 | Drug metabolism - cytochrome P450 | 4.697E-08 | 1.232E-06 | CYP2C9, CYP2D6, CYP1A2, CYP3A4, CYP2C19 |
| 09150 Organismal Systems | 09156 Nervous system | hsa04726 | Serotonergic synapse | 5.370E-07 | 7.026E-06 | CYP2C9, CYP2D6, ALOX15, CYP2C19, PTGS1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00983 | Drug metabolism - other enzymes | 5.576E-07 | 7.026E-06 | CDA, TK1, CYP3A4, XDH |
| 09100 Metabolism | 09103 Lipid metabolism | hsa00590 | Arachidonic acid metabolism | 1.876E-06 | 1.970E-05 | CYP2C9, ALOX15, CYP2C19, PTGS1 |
| 09100 Metabolism | 09111 Xenobiotics biodegradation and metabolism | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 3.620E-06 | 3.258E-05 | CYP2C9, CYP2D6, CYP1A2, CYP3A4 |
| 09160 Human Diseases | 09161 Cancers | hsa05204 | Chemical carcinogenesis | 5.765E-06 | 4.540E-05 | CYP2C9, CYP1A2, CYP3A4, CYP2C19 |
| 09100 Metabolism | 09108 Metabolism of cofactors and vitamins | hsa00830 | Retinol metabolism | 1.127E-04 | 7.100E-04 | CYP2C9, CYP1A2, CYP3A4 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00040 | Pentose and glucuronate interconversions | 1.240E-03 | 5.582E-03 | AKR1B10, AKR1B1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00052 | Galactose metabolism | 8.611E-04 | 4.521E-03 | AKR1B10, AKR1B1 |
| 09100 Metabolism | 09101 Carbohydrate metabolism | hsa00051 | Fructose and mannose metabolism | 9.801E-04 | 4.750E-03 | AKR1B10, AKR1B1 |
| 09100 Metabolism | 09102 Energy metabolism | hsa00910 | Nitrogen metabolism | 2.724E-04 | 1.560E-03 | CA12, CA9 |
| 09100 Metabolism | 09110 Biosynthesis of other secondary metabolites | hsa00232 | Caffeine metabolism | 2.025E-05 | 1.417E-04 | CYP1A2, XDH |
Human Diseases Associated with the Target Proteins of the Plant
Detailed Information of Human Diseases
| ICD10 Disease Category | Disease Name | ICD10 Code | Associated Disease Targets (Association Ref: TTD database) |
|---|---|---|---|
| A00-B99: Certain infectious and parasitic diseases | Adult varicella zoster virus infection | B02 | TK1; |
| I00-I99: Diseases of the circulatory system | Angina pectoris | I20 | F10; |
| C00-D49: Neoplasms | Renal cancer | C64 | F10; CA9; |
| C00-D49: Neoplasms | Cancer | C00-C96 | TK1; CA9; |
| C00-D49: Neoplasms | Brain cancer | C71, D33 | TK1; |
| I00-I99: Diseases of the circulatory system | Prophylaxis of deep vein thrombosis | I80-I82, I80.2 | F10; |
| C00-D49: Neoplasms | Prostate cancer | C61 | TK1; |
| NA: NA | Christmas disease | NA | F10; |
| I00-I99: Diseases of the circulatory system | Venous thrombosis | I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Deep venous clots | I80.2 | F10; |
| C00-D49: Neoplasms | Lymphoma | C81-C86 | CA9; |
| C00-D49: Neoplasms | Clear cell renal cell carcinoma | C64 | CA9; |
| I00-I99: Diseases of the circulatory system | Coagulation | I80-I82 | F10; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Cognitive disorders | F01-F07, F04, F05, R41.3 | MAPT; |
| I00-I99: Diseases of the circulatory system | Bleeding | I74, I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Cerebrovascular ischaemia | I61-I63 | F10; |
| G00-G99: Diseases of the nervous system G00-G99 | Central nervous system disease | G00-G99 | MAPT; |
| I00-I99: Diseases of the circulatory system | Venous thromboembolism | I80-I82 | F10; |
| G00-G99: Diseases of the nervous system G00-G99 | Alzheimer disease | G30 | MAPT; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hematology | D50-D77 | F10; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Hemophilia | D66-D68 | F10; |
| I00-I99: Diseases of the circulatory system | Thrombosis | I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Thromboembolism | I80-I82 | F10; |
| I00-I99: Diseases of the circulatory system | Acute coronary syndrome | I74 | F10; |
| I00-I99: Diseases of the circulatory system | Thromboembolic disorders | I80-I82 | F10; |
| C00-D49: Neoplasms | Pancreatic cancer | C25 | TK1; |
| F01-F99: Mental, Behavioral and Neurodevelopmental disorders | Attention deficit hyperactivity disorder | F90 | F10; |
| E00-E89: Endocrine, nutritional and metabolic diseases | Atrial fibrillation | E78, I48 | F10; |
| C00-D49: Neoplasms | Breast cancer | C50 | CA9; |
| D50-D89: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism | Blood coagulation disorders | D65-D68 | F10; |
| S00-T88: Injury, poisoning and certain other consequences of external causes | Graft-versus-host disease | T86.0 | TK1; |
| NA: NA | Haemophilia B | NA | F10; |
| C00-D49: Neoplasms | Solid tumours | C00-D48 | TK1; CDA; CA9; |
| I00-I99: Diseases of the circulatory system | Deep vein thrombosis | I80-I82, I80.2 | F10; |
| G00-G99: Diseases of the nervous system G00-G99 | Neurodegenerative disease | G30-G32 | MAPT; |
| C00-D49: Neoplasms | Acute myeloid leukemia | C92.0 | TK1; |
>> Profiles of ingredients and activity landscape
>> Targets derived from weak experimental activities
